Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Imagine that you've been diagnosed with a debilitating eye disease. Your vision suddenly decreases, and you can no longer clearly see your loved ones or the things that matter most to you. It can be a frightening experience.
This irreversible loss of vision, which is a symptom of eye diseases such as glaucoma, occurs when the neurons (nerve cells) that control sight are destroyed.
While researchers still do not know the exact mechanism by which this occurs, there is evidence to suggest that the accumulation of toxic reactive oxygen species is involved. These toxic compounds damage light-sensitive neurons through a process called oxidative stress.
Luckily, the body has specialized cells (astrocytes) that help produce a powerful antioxidant, known as glutathione (GSH), that neutralizes the damaging effects of the reactive oxygen species.
Dr. Jeremy Sivak, Senior Scientist at Krembil Research Institute, has been searching for ways to promote the production of GSH in order to halt, prevent, or reverse vision loss in patients with eye disease.
His team recently discovered that a protein called adenosine monophosphate-activated kinase (AMPK) increases the production of GSH in astrocytes by activating another key protein known as PGC-1 alpha.
The researchers also demonstrated—using an experimental model of eye disease—that therapeutic compounds mimicking AMPK, increase GSH levels while reducing the death of neurons in the eye.
"Activating PGC-1 alpha represents a novel strategy for enhancing protective astrocyte activity in the eye," explains Dr. Sivak.
"It is an exciting discovery that could not only be applied to eye diseases such as glaucoma, but also other degenerative diseases—such as Alzheimer's disease—where neurons are damaged by oxidative stress."
This work was supported by the Canadian Institutes of Health Research, the Glaucoma Research Society of Canada, the Natural Sciences and Engineering Research Council of Canada and the Toronto General & Western Hospital Foundation. J. Sivak is the Toronto General & Western Hospital Foundation Glaucoma Research Chair.